REUTERS: The U.S. Food and Drug Administration declined to approve Sarepta Therapeutics Inc's newest treatment for Duchenne muscular dystrophy , a rare muscle-wasting disorder that mainly affects boys, the company said on Monday.
The health agency cited safety concerns, including risk of infection and kidney toxicity. The Cambridge, Massachusetts-based company already has one approved treatment for DMD on the market.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: